Predicine offers quick COVID-19 RT-PCR and IgM/IgG antibody tests.
Predicine’s liquid biopsy tests are designed to be applied across various tumor types for guiding treatment selection, detecting minimal residual disease, and monitoring treatment efficacy and resistance. We have a number of ongoing research projects with leading institutions.
Predicine’s liquid biopsy assays were deployed in many clinical trials and research studies in which a limited amount of plasma from each patient was available. Many of these samples volumes are as little as 1 – 2mL. Predicine’s proprietary platform enables cfDNA detection at very low input volume. This helps to preserves precious samples without compromising valuable molecular insights from retrospective and prospective studies.
Please use the form below to submit your questions, comments, or inquiries about potential studies. We will get back to you within 24 hours.